Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAX576 vs infliximab for perianal fistulas in Crohn's disease
2010-019973-13Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dectrekumab in Crohn's disease and anal fistula (2 arms), sponsored by Novartis. Primary endpoint: Complete fistula closure. Started Sep 2010; status: terminated.
02
Drugs
dectrekumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on 2010-019973-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019973-13.